Ambion has recently introduced the ArrayScript reverse transcriptase, a modified enzyme that the company said produces “up to twice as much cRNA as wild-type M-MLV or AMV and other engineered M-MLV reverse transcriptases when low amounts of total RNA are used.”
Details on the product can be found at . http://www.ambion.com/catalog/CatNum.php?2048.
Acacia Research said this week that its CombiMatrix unit has introduced a new CustomArray human drug metabolism array, which allows for the screening of a panel of genes and splice variants that play a role in pharmacokinetics and drug metabolism.
According to the company, the array covers the Cytochrome p450 gene family, UDP-glucuronosyl-transferases, glutathione-transferases, sulfo-transferases, and N-acetyl-transferases.
“This catalog array, for drug metabolism, is the first in a series of catalog arrays which we will be releasing over the coming months,” Amit Kumar, president and CEO of CombiMatrix, said in a statement.
MWG Biotech said this week that it will begin distributing its ExpressArt line of mRNA amplification kits globally, excluding Great Britian, Japan, and Switzerland, beginning in September.
The kits, said the company, cover the full range of input total RNA and are available in three versions for nanogram, picogram, and microgram amounts of RNA.
Additional kits for the amplification of bacterial mRNA, severely degraded RNAs from difficult samples, and RNAs from paraffin-embedded tissues will be launched before the end of the year, MWG said.
The ExpressArt line was developed using technology from Artus.